|
|
 |
 |
| |
 Printable version |
Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study |
Bulletin du Cancer. Volume 98, Number 9, 80-9, Septembre 2011, Electronic journal of oncology
|
 Full Text
|
Author(s) : Irène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, Jean-Paul Guastalla, Pierre Meeus, Olivier Tredan, Intidhar Labidi Galy, Isabelle Moullet, Philippe Ardisson, Lionel Vincent, David Coeffic, Armelle Dufresne, Jean-Pierre Bergerat, Isabelle Ray-Coquard |
Summary : <\;p>As vascular endothelial growth factor (VEGF) is expressed in ovarian cancer, we assessed the efficacy and safety of bevacizumab (a monoclonal antibody targeting VEGF) plus microtubule targeting agents for heavily pre-treated ovarian carcinoma patients.<\;/p><\;p>We retrospectively reviewed 43 patients with recurrent epithelial ovarian carcinoma. Combined treatment included bevacizumab with paclitaxel in 32 (74%), docetaxel in 10 (23%), and vinorelbine in one (2.3%) patients, respectively.<\;/p><\;p>The median number of combined treatment was six cycles (range 1-29). On RECIST criteria, the objective response rate (ORR) was 40% (16% CR and 24% PR). Clinical benefit (complete response [CR] plus partial response [PR] and stable disease [SD] lasting ≥ 3 months) was 74% (CI95%: 46.7-77%). Median duration of treatment and overall survival were 3.9 months (range 0.2-14.4 months) and 20.1 months (CI95%: 13.8-20.1) respectively. No toxic death was reported. Grade 3-4 toxicity occurred in 30% of patients. Gastrointestinal perforations and fistula occurred in 3 (7%) and 6 (14%) patients, respectively.<\;/p><\;p>Although being active in terms of ORR, bevacizumab plus microtubule targeting agents – mainly taxanes – leads to a high rate of gastro-intestinal perforations and fistula in heavily pre-treated ovarian carcinoma patients.<\;/p> |
Keywords : bevacizumab, microtubule targeting agents, ovarian cancer, gastro-intestinal perforations |
|
